Second-line hormonal therapy for advanced prostate cancer: A shifting paradigm

Journal of Clinical Oncology

Volumn 15, Issue 1, 1997, Pages 382-388

  Small, E J ^a   Vogelzang, N J ^a  

^a UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOGLUTETHIMIDE; ANTIANDROGEN; BICALUTAMIDE; FLUTAMIDE; GLUCOCORTICOID; KETOCONAZOLE; MEGESTROL ACETATE; PREDNISONE; PROSTATE SPECIFIC ANTIGEN;

CANCER HORMONE THERAPY; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDICATION; DRUG WITHDRAWAL; HUMAN; PRIORITY JOURNAL; PROSTATE CANCER; REVIEW; TREATMENT INDICATION;

EID: 0031017228     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.1997.15.1.382     Document Type: Review

References (39)

1. Parker SL, Tong T, Bolden S, et al: Cancer Statistics, 1996. CA Cancer J Clin 65:5-27, 1996
2. Gittes R: Carcinoma of the prostate. N Engl J Med 324:236-245, 1991
3. Crawford ED, Eisenberger MA, McLeod DG, et al: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419-424, 1989
4. Maximum androgen blockade in advanced prostate cancer: An overview of 22 randomized trials with 3283 deaths in 5710 patients. Prostate Cancer Trialists' Collaborative Group. Lancet 346:265-269, 1995
5. Eisenberger MA, Simon R, O'Dwyer PJ, et al: A reevaluation of nonhormonal cytotoxic chemotherapy in the treatment of prostatic carcinoma. J Clin Oncol 3:827-841, 1985
6. Tannock IF: Is there evidence that chemotherapy is of benefit to patients with carcinoma of the prostate? Proc Am Soc Clin Oncol 12:234, 1985 (abstr)
7. Murphy GP, Beckley S, Brady MF, et al: Treatment of newly diagnosed metastatic prostate cancer patients with chemotherapy agents in combination with hormones versus hormones alone. Cancer 51:1264-1272, 1983
8. Kelly WK, Scher HI, Mazumdar M: Prostate-specific antigen as a measure of disease outcome in metastatic hormone-refractory prostate cancer. J Clin Oncol 11:607-615, 1993
9. Scher HI, Curley T, Geller N, et al: Trimetrexate in prostatic cancer: preliminary observations on the use of prostate-specific antisen and acid phosphatase as a marker in measurable hormone-refractory disease. J Clin Oncol 8:1830-1838, 1990
10. Sridhara R, Eisenberger MA, Sinibaldi VJ, et al: Evaluation of prostate specific antigen as a surrogate marker for response of hormone-refractory prostate cancer to suramin therapy. J Clin Oncol 13:2944-2953, 1995
11. Tannock I, Osoba D, Stockier MR, et al: Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: A Canadian randomized trial with palliative end points. J Clin Oncol 14:1756-1764, 1996
12. Fowler JE, Pandey P, Seaver LE, Feliz TP: Prostate specific antigen after gonadal androgen withdrawal and deferred flutamide treatment. J Urol 154:448-453, 1995
13. Kocuk O, Blumenstein B, Moinpour C, et al: Phase II trial of Casodex in advanced prostate cancer patients who failed conventional hormonal manipulation: A Southwest Oncology Group study. Proc Am Soc Clin Oncol 15, 1996 (abstr)
14. Dawson NA: Treatment of progressive metastatic prostate cancer. Oncology 7:17-25, 1993
15. Scher HI, Steineck G, Kelly WK: Hormone-refractory (D3) prostate cancer: Refining the concept. Urology 46:142-148, 1995
16. Kobayashi K, Yokes EE, Vogelzang NJ, et al: Phase I study of suramin given by intermittent infusion without adaptive control in patients with advanced cancer. J Clin Oncol 13:2196-2207, 1995
17. Reyno LM, Egorin MJ, Eisenberger MA, et al: Development and validation of a pharmacokinetically based fixed dosing scheme for suramin. J Clin Oncol 13:2187-2195, 1995
18. Kelly WK, Curley T, Leibertz C, et al: Prospective evaluation of hydrocortisone and suramin in patients with androgen-independent prostate cancer. J Clin Oncol 13:2208-2213, 1995
19. Hudes GR, Greenberg R, Krigel RL: Phase II study of estramustine and vinblastine, two microtubule inhibitors in hormone-refractory prostate cancer. J Clin Oncol 10:1754-1761, 1992
20. Seidman AD, Scher HI, Petrylak D, et al: Estramustine and vinblastine: Use of prostate specific antigen as a clinical trial end point for hormone refractory prostatic cancer. J Urol 147:931-934, 1992
21. Pienta KJ, Redman B, Hussain M, et al: Phase II evaluation of oral estramustine and oral etoposide in hormone-refractory adenocarcinoma of the prostate. J Clin Oncol 12:2005-2012, 1994
22. Smith DC, Bahnson RR, Trump DL: Management of hormone-refractory disease, in Vogelzang NJ, Scardino PT, Shipley WU, et al (eds): Comprehensive Textbook of Genitourinary Oncology. Baltimore, MD, Williams & Wilkins, 1996
23. Kelly WK, Scher HI: Prostate specific antigen decline after antiandrogen withdrawal: The flutamide withdrawal syndrome. J Urol 149:607-609, 1993
24. Scher, HI, Kelly WK: Flutamide withdrawal syndrome: its impact on clinical trials in hormone-refractory prostate cancer. J Clin Oncol 11:1566-1572, 1993
25. Small EJ, Srinivas S: The antiandrogen withdrawal syndrome: Experience in a large cohort of unselected advanced prostate cancer patients. Cancer 76:1428-1434, 1995
26. Figg WD, Sartor O, Cooper MR, et al: Prostate specific antigen decline following discontinuation of flutamide in patients with stage D2 prostate cancer. Am J Med 98:412-414, 1995
27. Small EJ, Carroll PR: Prostate specific antigen decline after Casodex withdrawal: Evidence for an antiandrogen withdrawal syndrome. Urology 43:408-410, 1994
28. Dawson NA, McLeod DG: Dramatic prostate specific antigen decrease in response to discontinuation of megestrol acetate in advanced prostate cancer: Expansion of the antiandrogen withdrawal syndrome. J Urol 153:1946-1947, 1995
29. 2 prostate cancer (PCA). Proc Am Soc Clin Oncol 15:255, 1996 (abstr)
30. Taplin ME, Bubley GJ, Shuster TD, et al: Mutation of the androgen receptor gene in metastatic androgen-independent prostate cancer. N Engl J Med 332:1393-1398, 1995
31. Veldscholte J, Berrevoets CA, Mulder E: Studies on the human prostatic cancer cell line LNCaP. J Steroid Biochem Mol Biol, 49:341-346, 1994
32. Liebertz C, Kelly WK, Theodoulou M, et al: High dose Casodex for prostate cancer (pc): PSA declines in patients (pts) with flutamide withdrawal responses. Proc Am Soc Clin Oncol 14:232, 1995 (abstr)
33. Fenton MA, Rode P, Constantine M, et al: Bicalutamide for androgen-independent prostate cancer. Proc Am Soc Clin Oncol 15:262, 1996 (abstr)
34. Dawson NA, Small EJ, Winer EP, et al: Megestrol acetate (MA) in men with hormone-refractory prostate cancer (HRPC): Prostate specific antigen (PSA) response and antiandrogen withdrawal (AAWD) data: A Cancer and Leukemia Group B study. Proc Am Soc Clin Oncol 15:241, 1996 (abstr)
35. Sartor O, Cooper M, Weinberger M, et al: Surprising activity of flutamide withdrawal, when combined with aminoglutethimide, in treatment of "hormone-refractory" prostate cancer. J Natl Cancer Inst 86:222-227, 1994
36. Dupont A, Gomez JL, Cusan L, et al: Response to flutamide withdrawal in advanced prostate cancer in progression under combination therapy. J Urol 150:908-913, 1993
37. Small EJ, Baron AD, Pippin L, et al: Ketoconazole retains activity in advanced prostate cancer patients who have progressed despite flutamide withdrawal. J Urol 1996 (in press)
38. Tannock I, Gospodarowicz M, Meakin W, et al: Treatment of metastatic prostate cancer with low-dose prednisone: Evaluation of pain and quality of life as pragmatic indices of response. J Clin Oncol 7:590-597, 1989
39. Dawson NA, Cooper MR, Figg WD, et al: Antitumor activity of suramin in hormone-refractory prostate cancer when hydrocortisone treatment and flutamide withdrawal are prospectively controlled for as potentially confounding variables. Cancer 76:453-462, 1995